MMF After Pediatric Liver Transplantation

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver transplantation is one of the main causes of chronic kidney disease in these patients in the long term.

The study objective is the evaluation of safety of a modification in immunosuppression from a dual-immunosuppression (CSA or FK plus steroids) to a triple immunosuppression (MMF plus CSA (reduced dosage) plus steroids.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hannover Medical School

Criteria

Inclusion Criteria:

• patients after pediatric liver transplantation

• no acute rejections for the last half year

Exclusion Criteria:

• concomitant malign disease (e.g. ptld)

• neutropenia (granulocytes <1000/µl)

• systemic infection

• thrombopenia (<80/nl)